Skip to content

Released Nov 4, 2021, after the close

10-Q filed Nov 4, 2021, 35 days after period end · 0001564590-21-054499

Q3 2021 · 10-Q
Revenue$6.25M−81.9% vs Q3 2020no prior Q2 2021 on file
Net Income-$18.80MN/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.41N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$18,875,000N/M
Operating Cash Flowderived-$18,882,000N/M
Free Cash Flowderived-$18,882,000N/M
Margins · derived
Operating margin-301.8%−290.2 pt vs Q3 2020
Net margin-300.7%−291.0 pt vs Q3 2020

What the release said

The release

Same quarter

MetricQ3 2021Q3 2020Q3 2019Q3 2018
Revenue$6.25M$34.61M$4.23M$4.29M
Net Income-$18.80M-$3.35M-$25.00M-$21.54M
EPS Diluted-$0.41-$0.09-$0.96-$0.87

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR